1887

Chapter 13 : Treatment of Community-Acquired Respiratory Tract Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Treatment of Community-Acquired Respiratory Tract Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap13-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap13-2.gif

Abstract:

The use of quinolones in respiratory tract infection (RTI) has developed from unpromising origins. A number of differing pathogens cause community-acquired pneumonia (CAP), which is not a homogeneous clinical entity. Fluoroquinolones refer primarily to three currently available agents: levofloxacin, gatifloxacin and moxifloxacin. A recent comprehensive review of in vitro and ex vivo models of pneumococcal infection found most to indicate positive outcomes at AUC/MIC values of 20 to 50, thus explaining the paradox of certain fluoroquinolones, such as levofloxacin, which failed to attain AUC/MIC ratios in keeping with previously recommended levels (125 or greater) yet proved highly effective in human infection. Analysis of bacteriologic results according to specific pathogens has shown that the quinolones, in particular, agents such as levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin, are at least comparable with control drugs for the treatment of infections caused by , , and other common pathogens. Of the various community-acquired RTIs, pharyngitis is one of the most common and carries a significant burden of illness. Of the infections described in this chapter, pharyngitis is the only one affecting the upper respiratory tract and it is responsible for 200 physician visits per 1,000 population annually. Acute bronchitis is primarily a viral or noninfective, pollution-related entity which occurs in patients with normal airways and, as such, does not routinely justify antibiotic therapy.

Citation: Ball P, Mandell L. 2003. Treatment of Community-Acquired Respiratory Tract Infections, p 227-243. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch13
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817817.chap13
1. Adams, S. G.,, J . Melo,, M. Luther,, and A. Anzueto. 2000. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117: 1345 1352.
2. Allegra, L.,, C. Grassi,, E. Grossi,, E. Pozzi,, F. Blasi,, D. Frigerio,, and A. Nastri. 1991. Ruolo degli antibiotici nel trattamento delle riacutizza della bronchite cronica. Ital. J. Chest. Dis. 45: 38 48.
3. Allegra, L.,, N. Konietzko,, P. Leophonte,, J. Hosie,, R. Pauwels,, J. N. Guyen,, and P. Petitpretz. 1996. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J. Antimicrob. Chemother. 37( Suppl. A): 93 104.
4. American Thoracic Society. 2001. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Respir. Crit. Care Med. 163: 17301754.
5. Andrews, J. M.,, D. Honeybourne,, G. Jevons,, N. P. Brenwald,, B. Cunningham,, and R. Wise. 1997. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 39: 797 802.
6. Andrews, J . M.,, D. Honeybourne,, G. Jevons,, N. P. Brenwald,, B. Cunningham,, and R. Wise. 1997. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral doses in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 40: 573 577.
7. Anie, K.,, K. Lowton,, and P. W. Jones. 1997. Changes in health status following an acute exacerbation of chronic bronchitis. Eur. Respir. J. 10( Suppl. 25): 148S.
8. Anthonisen, N. R.,, J . Manfreda,, C. P. W. Warren,, E. S. Hershfield,, G. K. M. Harding,, and N. A. Nelson. 1987. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106: 196 204.
9. Anzueto, A.,, M. S. Niederman,, and G. S. Tillotson. 1998. Etiology, susceptibility and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg bid versus clarithromycin 500 mg bid. Clin. Ther. 27: 722 729.
10. Anzueto, A.,, J . A. Rizzo,, and R. F. Grossman. 1999. The infection free interval: its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin. Infect. Dis. 28: 1344 1345.
11. Armstrong, G. L.,, and R. W. Pinner. 1999. Outpatient visits for infectious diseases in the United States, 1980 through 1996. Arch. Intern. Med. 159: 2531 2536.
12. Arroll, B.,, and B. Kenealy. 2001. Antibiotics for acute bronchitis. Brit. Med. J. 322: 939 940.
13. Aubier, M.,, H. Lode,, and G. Gialdroni-Grassi,, G. Huchon,, J. Hosie,, N. Legakis,, C. Reganey,, S. Segev,, R. Vester,, W. J. Wijnands,, and N. Tolstuchow. 1996. Sparfloxacin for the treatment of community acquired pneumonia: a pooled data analysis of two studies. J. Antimicrob. Chemother. 37( Suppl. A): 73 82.
14. Balgos, A. A., and the Consensus Group. 1998. Guidelines for the role of antibiotics in acute exacerbations of chronic bronchitis in the Asia Pacific region: report and recommendations of a consensus group. Med. Prog. 25: 29 38.
15. Ball, A. P.,, and G. S. Tillotson. 1995. Lower respiratory tract infection therapy: the role of ciprofloxacin. J. Int. Med. Res. 23: 315 327.
16. Ball, P.,, F. Baquero,, O. Cars, and the Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. in press.
17. Ball, P.,, S. Chodosh,, R. Grossman,, G. Tillotson,, and R. Wilson. 2000. Causes, epidemiology and treatment of bronchial infections. Infect. Med. 17: 186 198.
18. Ball, P.,, J. M. Harris,, D. Lowson,, G. Tillotson,, and R. Wilson. 1995. Acute infective exacerbations of chronic bronchitis. Q. J. Med. 88: 61 68.
19. Ball, P.,, R. Wilson,, L. Mandell, and the 069 Study Group. 2001. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. J. Chemother. 13: 288 298.
20. Ball, P.,, R. Wilson,, L. Mandell, and the Globe Study group. 2000. Gemifloxacin long term outcomes in bronchitis exacerbations (Globe) study—an assessment of health outcome benefits in AECB patients following 5 days gemifloxacin therapy, abstr. 812. Program and Abstracts of the 40 th Interscience Conference on Antimicrobial Agents and Chemotherapy . American Society for Microbiology, Washington, D.C.
21. Ball, P. 2000. Acute exacerbations of chronic bronchitis. Curr. Opin. Infect. Dis. 13: 171 176.
22. Ball, P., 2000. Acute exacerbations of chronic bronchitis: in search of a definition, p. 24 35 . In L. Allegra,, F. Blasi (ed.), Mechanisms and Management of COPD Exacerbations. Springer-Verlag, Milan, Italy.
23. Ball, P. 2000. Future antibiotic trials. Semin. Respir. Infect. 15: 82 89.
24. Ball, P. 1990. Overview of experience with ofloxacin in respiratory tract infection. Scan. J. Infect. Dis. Suppl. 68: 56 63.
25.Ball, P. 1991. The role of temafloxacin in the community: an overview. J. Antimicrob. Chemother. 28( Suppl. C): 121130.
26. Banerjee, D.,, and D. Honeybourne. 1999. The role of fluoroquinolones in chronic obstructive pulmonary disease. Curr. Opin. Infect. Dis. 12: 543 547.
27. Bartlett, J. G.,, R. F. Breiman,, L. A. Mandell,, and T. M. File, Jr. 1998. Community-acquired pneumonia in adults: guidelines for management. Clin. Infect. Dis. 26: 811 838.
28. Bartlett, J. G.,, S. F. Dowell,, L. A. Mandell,, and T. M. File, Jr.,, D. M. Musher,, and M. J. Fire. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31: 347 382.
29. Buckingham, S. C.,, S. P. Brown,, and V. H. Joaquin. 1998. Break-through bacteremia and menigitis during treatment parenterally with cephalosporins for pneumococcal pneumonia. J. Pediatr. 132: 174 176.
30. Carbon, C.,, H. Ariza,, W. J. Rabie,, C. R. Salvarezza,, D. Elkharrat,, M. Rangaraj,, and P. Decosta. 1999. Comparative study of levofloxacin and amoxycillin-clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clin. Microbiol. Infect. 5: 724 732.
31. Chen, D. K.,, A. McGreer,, J . C. de Azavedo,, D. E. Low, and the Canadian Bacterial Surveillance Network. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341: 233 239.
32. Chodosh, S.,, C. A. DeAbate,, D. Haverstock, and the Bronchitis Study Group. 2000. Short course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir. Med. 94: 18 27.
33. Chodosh, S.,, A. Schreurs,, G. Siami, and the Bronchitis Study Group. 1998. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 27: 730 738.
34. Chodosh, S.,, A. Schreurs,, G. Siami, and the Bronchitis Study Group. 1998. Randomised, double bind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 27: 733 739.
35. Chodosh, S. 1991. Treatment of acute exacerbations of chronic bronchitis: state of the art. Am. J. Med. 91( Suppl 6A): 87S 92S.
36. Christenson, B.,, P. Lundbergh,, J. Hedlund,, and A. Ortquist. 2001. Effects of a large scale intervention with influenza and 23-valent pneumococcal vaccination in adults aged 65 years or older: a prospective study. Lancet 357: 1008 1011.
37. Cook, P. J.,, J . M. Andrews,, R. Wise,, D. Honeybourne,, H. Moudgil. 1995. Concentrations of OPC-17116 (grepafloxacin), a new fluoroquinolone antibacterial in serum and lung compartments. J. Antimicrob. Chemother. 35: 317 326.
38. Cooper, R. J.,, Hoffman, J. R.,, Bartlett, J. G.,, R. E. Besser,, R. Gonzales,, J. M. Hickner,, and M. A. Sande. 2001. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann. Intern. Med. 134: 509 517.
39. Dajani, A.,, K. Taubert,, P. Ferrieri,, G. Peter,, and S. Shulman. 1995. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics 96: 758 764.
40. Davidson, R.,, R. Cavalcanti,, J. L. Brunton,, D. J. Bast,, J. C. S. de Azavedo,, P. Kibsey,, C. Fleming,, and D. E. Low. 2001. Levofloxacin treatment failures of pneumococcal pneumonia in association with resistance. N. Engl. J. Med., in press.
41. Davies, B. I.,, and F. P. V. Maesen. 1999. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in vitro activity. J. Antimicrob. Chemother. 43( Suppl. C): 83 90.
42. DeAbate, C. A.,, C. P. Mathew,, J. H. Warner,, A. Heyd,, D. Church. 2000. The safety and efficacy of short course (5- day) mocifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir. Med. 94: 1029 1037.
43. DeAbate, C. A.,, R. A. Mclvor,, P. McElvaine,, K. Skuba,, and P. F. Pierce. Gatifloxacin vs. cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. 1999. J. Respir. Dis. 20( Suppl. 11): S23 S29.
44. Dedicoat, M.,, and P. Venkatesan. 1999. The treatment of Legionnaire's disease. J. Antimicrob. Chemother. 43: 747 752.
45. Denny, F. W. Effect of treatment on streptococcal pharyngitis: is the issue really settled? 1985. Pediatr. Infect. Dis. 4: 352 354.
46. Despande, L. M.,, and R. N. Jones. 2000. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). Diagn. Microbiol. Infect. Dis. 37: 139 142.
47. Destache, C. J.,, N. Dewan,, W. J. O'Donohue,, J. C. Campbell,, and Angelillo. 1999. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 43( Suppl. A): 107 113.
48. Dowell, S. F.,, T. Smith,, K. Leversedge,, and J. Snitzer. 1999. Pneumonia treatment failure associated with highly resistant pneumococci. Clin. Infect. Dis. 29: 462 463.
49. Dresser, L. D.,, M. S. Niederman,, and J. A. Paladino. 2001. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest. 119: 1439 1448.
50. Eller, J.,, A. Ede,, T. Schaberg,, M. S. Niederman,, H. Mauch,, and H. Lode. 1998. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 113: 1542 1548.
51. Esposito, S.,, G. D'errico,, C. Montanaro. 1990. Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. J. Chemother. 2: 108 112.
52.European Respiratory Society. 1998. Guidelines for management of adult community-acquired lower respiratory tract infections. ERS Task Force Report. Eur. Respir. J. 11: 986991.
53. Fahey, T.,, N. Stocks,, and T. Thomas. 1998. Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults. Brit. Med. J. 316: 906 910.
54. Fang, G. D.,, M. Fine,, J . Orloff,, D. Arisumi,, V. L. Yu,, W. Kapoor,, J . T. Grayston,, S. P. Wang,, R. Kohler,, R. R. Muder, et al. 1990. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 69: 307 316.
55. Feikin, D.,, A. Schuchat,, M. Kolczak,, N. L. Barrett,, L. H. Harrison,, L. Lefkowitz,, A. McGeer,, M. M. Farley,, D. J. Vugian,, C. Lexau,, K. R. Stefonek,, J . E. Patterson,, and J . H. Jorgensen. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90: 223 229.
56. File, T. M.,, B. Schlemmer,, J . Garau,, M. Cupo,, C. Young, and the 049 Clinical Study Group. 2001. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 48: 67 74.
57. File, T. M.,, J. Segreti,, L. Dunbar,, R. Player,, R. Kohler,, R. R. Williams,, C. Kojak,, and A. Rubin. 1997. A multicenter, randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41: 1967 1972.
58. File, T.M. 1999. Acute bronchitis: indication for antibiotic avoidance. Curr. Opin. Infect. Dis. 12: 111 113.
59. Fine, M. J.,, T. E. Auble,, D. M. Yealy,, B. H. Hanusa,, L. A. Weissfeld,, D. E. Singer,, C. M. Coley,, T. J. Morrie,, and W. N. Kapoor. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336: 243 250.
60. Fine, M. J.,, M. A. Smith,, C. A. Carson,, S. S. Muthan,, S. S. Sankey,, L. A. Weissfeld,, and W. N. Kapoor. 1996. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 275: 134 141.
61. Fink, M. P.,, D. R. Snydman,, M. S. Niederman,, K. V. Leeper, Jr.,, R. H. Johnson,, S. O. Heard,, R. G. Wunderink,, J. W. Caldwell,, J. J. Schentag,, G. A. Siami, et al. 1994. Treatment of severe pneumonia in hospitalised patients: results of a multicenter, randomised, double blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimcrob. Agents Chemother. 38: 547 557.
62. Fogarty, C.,, M. E. Dowell,, W. T. Ellison, et al. 1999. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J. Respir. Dis. 20( Suppl): S60 S69.
63. Fogarty, C.,, C. Grossman,, J. Williams, and the Communityacquired Pneumonia Study Group. 1999. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect. Med. 16: 748 763.
64. Forrest, A.,, S. Chodosh,, M. A. Amantea,, D. A. Coillins,, J. J. Schentag. 1997. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40( Suppl. A): 45 57.
65. Forrest, A.,, D. E. Nix,, C. H. Ballow,, T. F. Goss,, M. C. Birmingham,, J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37: 1073 1081.
66.Gallagher. 1999. Abstr. 2246. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D. C.
67. Garau, J.,, J. R. Lonks,, L. Gomez,, M. Xercavins,, and A. A. Medeiros. 2000. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant streptococcus pneumoniae, abstr. N709. In 5th International Conference on Macrolides, Azalides and Streptogramins.
68. Garau, J. 2001. Data presented at the 5th International Moxifloxacin Symposium.
69. Garau, J. 2001. Data presented at the 5th International Moxifloxacin Symposium.
70. Garau, J. 2001. Clinical failures: the tip of the iceberg? Respir. Med., 95( Suppl. A): S3 S11.
71. Geddes, A. M.,, M. Thaler,, S. Schonwald,, M. Harkonen,, F. Jacobs,, and I. Nowotny. 1999. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open randomised trial. J. Antimicrob. Chemother. 44: 799 810.
72. Gonzalez, R.,, J. F. Steiner,, and M. A. Sande. 1997. Antibiotic prescribing for adults with colds, upper respiratory tract infection and bronchitis by ambulatory care physicians. JAMA 278: 901 904.
73. Graham, E.,, E. Whalen,, M. E. Smith, et al. 1994. Comparison of costs between ciprofloxacin and imipenem for the treatment of severe pneumonia in hospitalised patients. Pharmacotherapy 14: 370 371.
74. Grossman, R.,, J. Mukherjee,, D. Vaughan, and the Canadian Ciprofloxacin Health Economic Study Group. 1998. A 1 year community-based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113: 131 141.
75. Grossman, R. 1997. The role of fluoroquinolones in respiratory tract infections. J. Antimicrob. Chemother. 40( Suppl. A): 59 62.
76. Guay, D. R. 1993. Sequential antimicrobial therapy: a realistic approach to cost containment? Pharmacoeconomics 3: 341 344.
77. Habib, M. P.,, L. O. Gentry,, G. Rodriguez-Gomez, et al. 1998. Multicenter randomised study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect. Dis. Clin. Pract. 7: 101 109.
78. Halpern, M. T.,, C. S. Palmer,, M. Zodet,, J. M. Kirsch, and the Globe Study Group. 2001. Cost effectiveness of gemifloxacin versus clarithromycin in the treatment of AECB: the Globe study. J. Antimicrob. Chemother. 47( Suppl. S1): 43.
79. Hamm, R. M.,, R. J. Hicks,, and D. A. Bemben. 1996. Antibiotics and respiratory infections: are patients more satisfied when expectations are met. J. Fam. Pract. 43: 56 62.
80. Heffelfinger, J. D.,, S. F. Dowell,, J. H. Jorgensen,, K. P. Klugman,, L. R. Mabry,, D. M. Musher,, J . F. Plouffe,, A. Rakowsky,, A. Schuchat,, and C. G. Whitney. 2000. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug- Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160: 1399 1408.
81. Highet, V. S.,, A. Forrest,, C. H. Ballow,, J. J. Scentag. 1999. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J. Antimicrob. Chemother. 43( Suppl. A): 55 63.
82. Ho, P. L.,, R. W. H. Yung,, D. N. C. Tsang,, T. L. Que,, M. Ho,, W. H. Seto,, T. K. Ng,, W. C. Yam,, and W. W. Ng. 2001. Increasing resistance of Streptococcus pneumonia to fluoroquinolones: results of a Hong Kong multi-centre study in 2000. J. Antimicrob. Chemother. 48: 659 665.
83. Ho, P. L.,, T. L. Que,, D. N. Tsang,, T. K. Ng,, K. H. Chow,, and W. H. Seto. 1999. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrobial. Agents and Chemother. 43: 1310 1313.
84. Ho, P. L.,, W. S. Tse,, K. W. T. Tsang,, T. K., Kwok,, T. K. Ng,, V. C. Cheng,, and R. M. Chan. 2000. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case control study. Clin. Infect. Dis. 32: 701 707.
85. Honeybourne, D.,, D. Banerjee,, J. Andrews,, and R. Wise. 2001. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 48: 63 66.
86. Hyatt, J. M.,, A. B. Luzier,, A. Forrest,, C. W. Ballow,, and J. J. Schentag. 1997. Modeling the response of pneumonia to antimicrobial therapy. Antimicrob. Agents Chemother. 41: 1269 1274.
87. Janoir, C.,, V. Zeller,, M. D. Kitzis,, N. J. Moreua,, and L. Gutmann. 1996. High level fluoroquinolone resistance in Streptococcus pneumoniea requires mutations in par C and gyr A. Antimicrob. Agents Chemother. 40: 2760 2764.
88. Jardim J. R. for Consenso Latinamerico. 1997. Consenso Latinamerico sobre infecciones en bronquitis cronica. Rev. Panam. Infectol. 1: 1 19.
89. Jones, P.,, S. Spencer, and the Globe Study Group. 2001. Greater improvement in health status of smokers and exsmokers treated for AECB with gemifloxacin versus clarithromycin: the Globe Study. J. Antimicrob. Chemother. 47( Suppl. Sl): 43.
90. Kelley, M. A.,, D. J. Weber,, P. Gilligan,, M. S. Cohen. 2000. Break-through pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 31: 1008 1011.
91. Komaroff, A. L.,, T. M. Pass,, M. D. Aronson,, C. T. Ervin,, S. Cinetin,, R. N. Winickoff,, and W. T. Branch, Jr. 1986. The prediction of streptococcal pharyngitis in adults. J. Gen. Intern. Med. 1: 1 7.
92. Kreis, S. R.,, N. Herrera,, N. Golzar, and the Therapeutic Circles Bronchitis Study Group. 2000. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J. Clin. Outcomes Manage. 7: 33 37.
93. Lacy, M. K.,, W. Lu,, X . Xu,, P. R. Tessier,, D. P. Nicolau,, R. Quintiliani,, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43: 672 777.
94. Langan, C. E.,, P. Zuck,, F. Vogel,, A. Mclvor,, W. Peirzchala,, M. Smakal,, H. Staley, and C. Marr. 1999. Randomised, double blind study of short course (5 day) grepafloxacin versus lOd clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 44: 515 523.
95. Lee, B. L.,, A. M. Padula,, R. C. Kimbrough,, S. R. Jones,, R. E. Chaisson,, J . Mills,, M. A. Sande. 1997. Infectious complications with respiratory pathogens despite ciprofloxacin. N. Engl. J. Med. 325: 520 521.
96. Leophonte, P.,, R. J. T. Baldwin,, and N. Pluck. 1998. Trovafloxacin versus amoxicillin-clavulanic acid in the treatment of acute exacerbations of chronic bronchitis. Eur. J. Clin. Microbiol. Infect. Dis. 17: 434 440.
97. Leophonte, P.,, B. Schlemmer,, F. Goldstein,, J . Garau,, E. Roufhac, and The Gemifloxacin 011 Study Group. Efficacy and safety of once daily gemifloxacin (GEMI) for the treatment of community-acquired pneumonia (CAP) of suspected pneumococcal origin. French Meeting.
98. Leroy, O.,, C. Santre,, and C. Beuscart. 1995. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care. Med. 21: 24 31.
99. Li-McLeod, J.,, and E. M. Perfetto. 2001. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Managed Care Interface February: 505.
100. Lode, H.,, T. File,, L. Mandell,, P. Ball,, R. Pypstra, and The 185 Gemifloxacin Study Group. 2001. Comparative efficacy of oral gemifloxacin (GEM) and intravenous ceftriaxone (CTX) followed by oral cefuroxime (CFU) (± macrolide) in the treatment of community-acquired pneumonia (CAP). American College of Chest Physicians.
101. Lorenz, J.,, I. M. Thate-Waschke,, O. Mast,, R. Kubin,, R. Rychlik,, T. Pfeil,, D. Daniel,, and G. S. Tillotson. 2001. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patients perspective. J. Int. Med. Res. 29: 74 86.
102. Macfarlane, J.,, T. Boswell,, G. Douglas, et al. 2001. The British Thoracic Society Guidelines for the Management of Community-acquired Pneumonia in Adults. Thorax 56.
103. Macfarlane, J.,, W. Holmes,, R. Macfarlane,, and N. Britten. 1997. Influence of patients expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study. Br. Med. J. 315: 1211 1214.
104. Mandell, L. A.,, T. H. Marrie,, R. F. Grossman,, A. W. Chow,, and R. H. Hyland, and the Canadian Community-Acquired Pneumonia Working Group. 2000. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Clin. Infect. Dis. 31: 383 421.
105. Mandell, L. A.,, M. S. Niederman. 1993. The Canadian Community-acquired Pneumonia Consensus Conference Group, Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can. J. Infect. Dis. 4: 25 28.
106. Marras, T. K.,, L. Lee-Pack,, L. Jamieson,, and C. K. Chan. 2001. Effect of new guidelines and a respiratory quinolone on clinical outcomes in hospitalised patients with community- acquired pneumonia. J. Antimicrob. Chemother. 47( Suppl. Sl): 44 45.
107. Marrie, T. J.,, C. Y. Lau,, S. Wheeler,, C. J. Wong,, M. K. Vandervoort,, B. G. Feagan, and the Capital Study Investigators. 2000. A controlled trial of a critical pathway for treatment of community acquired pneumonia. JAMA 283: 749 755.
108. Marrie, T. J. 1994. Community-acquired pneumonia. Clin. Infect. Dis. 18: 501 515.
109. Marston, B. J.,, J . F. Plouffe,, T. M. File, Jr.,, B. A. Hackman,, S. J. Salstrom,, H. B. Lipman,, M. S. Kolczak,, and R. F. Breiman. 1997. Incidence of community-acquired pneumonia requiring hospitalization. Arch. Intern. Med. 277: 1214 1218.
110.McGuire, A. 1998. Burden and cost of LRTI: a methodologic overview. Infect. Med. 15( Suppl. E): 2633.
111. Miravitles, M., 2000. Designing future clinical trials for exacerbations of chronic bronchitis, pp 88 89. In L. Allegra,, and F. Blasi (ed.), Mechanisms and Management of COPD Exacerbations. Springer-Verlag, Milan, Italy.
112. Moine, P.,, J.-B. Vercken,, S. Chevret,, C. Chastang,, and P. Gajdos. 1994. Severe community-acquired pneumonia: Etiology, epidemiology and prognostic factors. Chest 105: 1487 1495.
113. National Centre for Health Statistics. 1998. National Hospital Discharge Survey: Annual Summary 1996. Vital Health Stat. 13: 1225.
114. Niederman, M.,, D. Church,, J . Kaufmann,, and M. Springsklee. 2000. Does appropriate antibiotic treatment influence outcome in community acquired pneumonia? Respir. Med. 94( Suppl. A): A14.
115. Niederman, M.,, S. Traub,, W. T. Ellison,, and D. J. Williams. Comparison of IV alatrofloxacin/oral trovafloxacin with IV ceftriaxone/oral cefpodoxime in hoispitalised patients with community acquired pneumonia. Am. J. Resp. Crit. Care Med., in press.
116. Niederman, M. S.,, J . B. Bass, Jr.,, G. D. Campbell,, A. M. Fein,, R. F. Grossman,, L. A. Mandell,, T. J. Marrie,, G. A. Sarosi,, A. Torres,, and V. L. Yu. 1993. American Thoracic Society Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am. Rev. Respir. Dis. 148: 1418 1426.
117. Niederman, M. S., 2000. Infection and antibiotic treatment in acute exacerbations of chronic bronchitis, p. 73 87. In L. Allegra, and F. Blasi, (ed.) Mechanisms and Management of COPD Exacerbations. Springer-Verlag, Milan, Italy.
118. Norrby, S. R.,, W. Petermann,, P. A. Willcox,, N. Vetter,, and E. Salewski. 1998. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalised patients with pneumonia. Scand. J. Infect. Dis. 30: 397 404.
119. O'Doherty, B.,, and R. Daniel. 1998. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double blind, double dummy study. Eur. J. Clin. Microbiol. Infect. Dis. 17: 441 446.
120. O'Doherty, B.,, D. A. Dutchman,, R. Pettit, et al. 1997. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J. Antimicrob. Chemother. 40( Suppl. A): 73 81.
121. Orr, P. H.,, K. Scherer,, A. MacDonald,, and M. E. K. Moffat. 1993. Randomised placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature. J. Earn. Pract. 36: 507 512.
122. Ortqvist, A.,, M. Valtonen,, and O. Cars, et al. 1996. Oral empiric treatment of community-acquired pneumonia: a multicentre, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest 110: 1499 1506.
123. Pachon, J.,, M. D. Prados,, F. Capote,, J. A. Cuello,, J. Garnacho,, and A. Verano. 1990. A. Severe communityacquired pneumonia: Etiology, prognosis and treatment. Am. Rev. Respir. Dis. 142: 369 373.
124. Paladino, J. A.,, H. E. Sperry,, J. M. Backes,, J. A. Gelber,, D. J. Serrianne,, T. J Cumbo,, and J. J. Schentag. 1991. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am. J. Med. 91: 462 470.
125. Paladino, J. A. 1995. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. Can. J. Hosp. Pharm. 48: 276 283.
126. Pechere, J. C. 1998. Modeling and predicting clinical outcomes of antibiotic therapy. Infect. Med. 15( Suppl. E): 46 54.
127. Petipretz, P.,, P. Arvis,, M. Mavel,, J. Moita,, J. Ureueta, and CAP5 Moxifloxacin Study Group. 2001. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild to moderate community-acquired, suspected pneumococcal pneumonia in adults. Chest 119: 185 195.
128. Pihlajamaki, M.,, P. Kotilainen,, T. Kaurila,, T. Klaukka,, E. Palva,, and P. Huovinen. 2001. Macrolide resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin. Infect. Dis. 33: 483 88.
129. Portier, H.,, T. May,, A. Proust, and the French Study Group. 1996. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community acquired pneumonia. J. Antimicrob. Chemother. 37( Suppl. A): 83 91.
130. Poses, R. M.,, R. D. Cebul,, M. Collins,, and S. S. Fager. 1985. The accuracy of experienced physician's probability estimates for patients with sore throats: implications for decision making. JAMA 254: 925 929.
131. Preston, S. L.,, G. L. Drusano,, A. L. Berman, et al. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42: 1098 1104.
132. Preston, S. L.,, G. L. Drusano,, A. L. Berman,, C. L. Fowler,, A. J. Chow,, B. Dornseif,, V. Reichl,, J . Natarajan,, F. A. Wong,, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279: 125 129.
133. Quintilliani, R.,, and C. Nightingale. 1994. Transitional antibiotic therapy. Infect. Dis. Clin. Pract. 3( Suppl. 3): S161 S167.
134. Ramirez, A.,, J. Molina,, A. Dolmann, et al. 1999. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: clinical trial results. J. Respir. Dis. 20( Suppl. 11): S30 S9.
135. Ramirez, J. A.,, T.-H. Nguyen,, G. Tellier, et al. 1999. Treating community-acquired pneumonia with once daily gatifloxacin vs twice daily clarithromycin. J. Respir. Dis. 20( Suppl.): S40 48.
136. Romanowski, B.,, J. S. Hardy,, M. S. Rafter,, J . Draker. Enoxacin in the therapy of anal and pharyngeal gonococcal infections. Sex. Transm. Dis. Vol. 16, No. 4: 190 191.
137. Saint, S.,, S. Bent,, E. Vittinghof,, D. Grady. 1995. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 273: 957 960.
138. Santos, J.,, B. Siquier,, J. Duran,, J. Custardoy,, A. Gil-Aguado,, C. Garcia-Rey,, L. Aguilar and The 049 CAP Collaborative Study Group. 2001. Usefulness of new quinolones in the treatment of Legionella pneumonia: a report of 28 cases. Progr. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother . American Society for Microbiology, Washington, D.C.
139. Schentag, J. J.,, D. E. Nix, and M. H. Adelman. 1991. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann. Pharmacother. 25: 1050 1057.
140. Schentag, J. J. 2000. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin. Infect. Dis. 31( Suppl. 2): S40 S44.
141. Sethi, S. 1999. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother. 43( Suppl. A): 97 105.
142. Shah, P. M.,, F. P. V. Maesen,, A. Dolmann,, N. Vetter,, E. Fiss,, and R. Wesch. 1999. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomised, double-blind study. J. Antimicrob. Chemother. 43: 529 539.
143. Smucny, J.,, T. Fahey,, L. Becker,, R. Glazier,, and W. Mclsaac. Antibiotics for acute bronchitis (Cochrane Review). In Cochrane Collaboration . Cochrane Database System Revision 2000. 4:CD000245.
144. Snellman, L. W.,, H. J. Stang,, J. M. Stang,, D. R. Johnson,, and E. L. Kaplan. 1993. Duration of positive throat cultures for group A streptococci after initiation of antibiotic therapy. Pediatrics 91: 1166 1170.
145. Soman, A.,, D. Honeybourne,, J. Andrews,, G. Jevons,, and R. Wise. 1999. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 44: 835 838.
146. Spencer, S.,, K. Anie,, and P. W. Jones. 1999. Annual rate of health status decline in COPD patients is significantly related to frequency of acute exacerbations. Eur. Respir. J. 14( Suppl. 30): 19S.
147. Sullivan, J.,, J. Gezon,, J. Herrod, et al. A randomized double blind trial of trovafloxaxcin versus clarithromycin in community acquired pneumonia.
148. Sullivan, J. G.,, A. D. McElroy,, R. W. Honsinger, et al. 1999. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J. Respir. Dis. 20.
149. Thiadens, H. A.,, G. H. de Bock,, F. W. Dekker,, J . A. Huysman,, J. C. van Houwelingen,, M. P. Springer,, and D. S. Postma. 1998. Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study. Br. Med. J. 316: 1286 1290.
150. Thomas, J. K.,, A. Forrest,, S. M. Bhavnani,, J. M. Hyatt,, A. Cheng,, C. H. Ballow,, and J. J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42: 521 527.
151. Tremolieres, F.,, F. de Kock,, N. Pluck,, and R. Daniel. 1998. Trovafloxacin versus high dose amoxicillin (lg three times daily) in the treatment of community-acquired bacterial pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 17: 447 453.
152. 1997. Trovafloxacin Abstract Reduced Mortality. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
153. Turret, G. L.,, S. Blum,, B. A. Fazal,, J. E. Justman,, E. E. Telzak. 1999. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin. Infect. Dis. 29: 321 327.
154. Van Barlingen, H. J. J.,, M. J. C. Nuijten,, T. Volmer et al. 1998. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany. J. Med. Econ. 1: 210 218.
155.Vogel, F. 1998. Cost benefits from improving clinical outcome. Infect. Med. 15( Suppl. E): 6167.
156. Weiss, K.,, C. Restieri,, R. Gauthier,, M. Laverdiere,, A. McGeer,, R. J. Davidson,, L. Kilburn,, D. J. Bast,, J . de Azavedo,, and D. E. Low. 2001. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae . Clin. Infect. Dis. 33, 517 522.
157. Weiss, M. C.,, R. Fitzpatrick,, D. K. Scott,, and M. J. Goldacre. 1996. Pressures on the general practitioner and decisions to prescribe. Earn. Pract. 13: 432 438.
158. Wilson, R.,, P. Ball,, and L. Mandell, and the Globe Study Group. 2000. Efficacy of once daily gemifloxacin (GEMI) for 5 days compared with twice daily clarithromycin (CLARI) for 7 days in the treatment of AECB, abstr. 815. Prog. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
159. Wilson, R.,, R. Kubin,, I. Ballin,, K. M. Deppermann,, H. P. Bassaris,, P. Leophonte,, A. J. Schreurs,, A. Torres,, and B. Sommerauer. 1999. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 44: 501 513.
160. Wise, R.,, and D. Honeybourne. 1996. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J. Antimicrob. Chemother. 37( Suppl. A): 57 63.
161. Wise, R. 1999. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin. Drug. Invest. 17: 365 387.
162. Woodhead, M. A.,, J. Arrowsmith,, R. Chamberlain-Webber, et al. 1991. The value of routine microbial investigation in community-acquired pneumonia. Respir. Med. 85: 313 317.
163. Wortmann, G. W.,, and S. P. Bennett. 1999. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae . Clin. Infect. Dis. 29: 1599 1600.
164. Wright, D. H.,, G. H. Brown,, M. L. Peterson,, and J . C. Rotschafer. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46: 669 684.

Tables

Generic image for table
Table 1

Peak quinolone concentrations in serum and in pulmonary tissues, fluids, and cells

Citation: Ball P, Mandell L. 2003. Treatment of Community-Acquired Respiratory Tract Infections, p 227-243. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch13
Generic image for table
Table 2

Results of oral quinolone therapy for CAP

Citation: Ball P, Mandell L. 2003. Treatment of Community-Acquired Respiratory Tract Infections, p 227-243. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch13
Generic image for table
Table 3

Results of parenteral quinolone therapy for CAP

Citation: Ball P, Mandell L. 2003. Treatment of Community-Acquired Respiratory Tract Infections, p 227-243. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch13
Generic image for table
Table 4

Clinical efficacy and bacteriological eradication rates in selected trials of pneumococcal CAP

Citation: Ball P, Mandell L. 2003. Treatment of Community-Acquired Respiratory Tract Infections, p 227-243. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch13
Generic image for table
Table 5

Results of oral quinolone therapy for acute exacerbations of chronic bronchitis

Citation: Ball P, Mandell L. 2003. Treatment of Community-Acquired Respiratory Tract Infections, p 227-243. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch13

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error